Phase 1 study of safety and preliminary efficacy of intranasal transplantation of human neural stem cells (ANGE-S003) in Parkinson's disease.
Shenzhong JiangHan WangChengxian YangFeng FengDan XuMengyu ZhangManqing XieRuixue CuiZhaohui ZhuChenhao JiaLinwen LiuLin WangXunzhe YangYingmai YangHonglin HaoZhaoxi LiuZhihong WuLing LengXiaoxin LiXicai SunXiongfei ZhaoJinfang XuYi ZhangXinhua WanXinjie BaoRenzhi WangPublished in: Journal of neurology, neurosurgery, and psychiatry (2024)
Treatment with ANGE-S003 is feasible, generally safe and well tolerated, associated with functional improvement in clinical outcomes with peak efficacy achieved at month 6. Intranasal transplantation of neural stem cells represents a new avenue for the treatment of PD, and a larger, longer-term, randomised, controlled phase 2 trial is warranted for further investigation.